Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elranatamab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | - |
| Phase 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Elranatamab | DRUG | Specified dose on specified days |
| Mezigdomide | DRUG | Specified dose on specified days |
| Dexamethasone | DRUG | Specified dose on specified days |
Inclusion Criteria: * Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2). * Measurable MM by local laboratory. * Eastern Cooperative Oncology Group performa...
Top 20 of 25 competitors
Elranatamab is an investigational drug being studied for the treatment of multiple myeloma. It is currently in Phase 1 clinical development, specifically being evaluated in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma. The drug is not yet approved and remains under clinical investigation.
Elranatamab targets CD3E, CD3G, CD3D, and TNFRSF17. These are components of the T-cell receptor complex and B-cell maturation antigen, respectively. By binding to these targets, the drug is designed to engage the immune system against myeloma cells, though its exact mechanism is still under study in clinical trials.
Elranatamab is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY on the stock exchange. The company is currently conducting a Phase 1 clinical trial to evaluate the drug's safety and preliminary efficacy in patients with relapsed and/or refractory multiple myeloma.
Elranatamab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to determine the recommended dose and schedule, and to evaluate safety and preliminary efficacy in combination with mezigdomide for multiple myeloma.
Elranatamab is being studied in one active clinical trial with the identifier NCT06988488. This Phase 1 study is recruiting participants with relapsed and/or refractory multiple myeloma across multiple countries, including the United States, Canada, China, Germany, Greece, Norway, Spain, and the United Kingdom. The trial has an enrollment target of 62 participants.
No, Elranatamab is not the same as mezigdomide. Elranatamab is the investigational drug being studied, while mezigdomide is a separate agent used in combination with it. The ongoing clinical trial evaluates the safety and preliminary efficacy of mezigdomide in combination with Elranatamab in patients with relapsed and/or refractory multiple myeloma.